Results 271 to 280 of about 574,921 (308)
Some of the next articles are maybe not open access.
Recombinant monoclonal antibody technology
Transfusion Clinique et Biologique, 2002With the development of murine hybridoma technology over a quarter century ago, the ability to produce large quantities of well-characterized monoclonal antibody preparations revolutionized diagnostic and therapeutic medicine. For many applications in transfusion medicine, however, the production of serological reagents in mice has certain biological ...
openaire +2 more sources
Manufacture of recombinant polyclonal antibodies
Biotechnology Letters, 2007Polyclonal antibody therapy in the form of hyper-immune serum has for more than a century been used for treatment of many infectious diseases. However, with the emergence of first antibiotics and later recombinant monoclonal antibody therapy, the use of hyper-immune serum has declined.
S K, Rasmussen +3 more
openaire +2 more sources
Recombinant antibodies for cancer therapy
Expert Opinion on Biological Therapy, 2008Recombinant antibodies have evolved into successful therapeutics with 10 approved for cancer and more in the pipeline. Four of the top ten cancer therapy drugs are recombinant antibodies.To survey the current state-of-the-art highlighting the reasons for this success and looking ahead to the next generation of antibody therapy.An analysis was carried ...
openaire +2 more sources
The Structure of Natural and Recombinant Antibodies
2015Immunoglobulins (Ig) isotypes A, D, E, G, and M are glycoproteins which are mainly composed of a "Y"-shaped Ig monomer (~150 kDa), consisting of two light and two heavy chains. Both light and heavy chains contain variable (N-terminal) and constant regions (C-terminal).
Hui, Ma, Richard, O'Kennedy
openaire +2 more sources
Intracellular Immunization with Cytosolic Recombinant Antibodies
Bio/Technology, 1994We report the application of a strategy to inactivate cellular proteins in vertebrate cells based on the intracellular expression of immunoglobulin genes. We have selected, in this instance, the p21 protein, encoded by the ras proto-oncogene, as a target protein.
BIOCCA S +3 more
openaire +3 more sources
Selection of Recombinant Human Antibodies
2015Since the development of therapeutic antibodies the demand of recombinant human antibodies is steadily increasing. Traditionally, therapeutic antibodies were generated by immunization of rat or mice, the generation of hybridoma clones, cloning of the antibody genes and subsequent humanization and engineering of the lead candidates.
Florian, Tomszak +5 more
openaire +2 more sources
Vacuolar Targeting and Characterization of Recombinant Antibodies
2018Plant-based platforms are extensively use for the expression of recombinant proteins, including monoclonal antibodies (mAbs). Generally, immunoglobulins (Igs) are sorted to the apoplast, which is often afflicted with intense proteolysis. Here, we describe methods to transiently express mAbs sorted to central vacuole in Nicotiana benthamiana leaves and ...
Ocampo, Carolina Gabriela +1 more
openaire +3 more sources
Glycosylation of Recombinant Antibody Therapeutics
Biotechnology Progress, 2008The adaptive immune system has the capacity to produce antibodies with a virtually infinite repertoire of specificities. Recombinant antibodies specific for human targets are established in the clinic as therapeutics and represent a major new class of drug.
openaire +2 more sources
Recombinant Proteins and Monoclonal Antibodies
2017The human genome has become a subject of public interest, whilst the proteome remains the province of specialists. Less appreciated is the human glycoprotein (GP) repertoire (proteoglycome!); however, some 50% of open reading frame genes encode for proteins (P) that may accept the addition of N-linked and/or O-linked sugar chains (oligosaccharides). It
openaire +2 more sources
Recombinant antibodies: back to the future
Australian and New Zealand Journal of Medicine, 1993Ward, R. L., Hawkins, N. J.
openaire +5 more sources